Publication | Open Access

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

UrologyGenitourinary CancerMedicinePathologyBevacizumab Versus SunitinibImmune Checkpoint InhibitorRenal Cell CarcinomaAnti-cancer AgentOncologyRadiation OncologyClinical ActivityMolecular Oncology